Validation of Biochemical Markers for the Prediction of Liver Fibrosis and Necroinflammatory Activity in Hemodialysis Patients with Chronic Hepatitis C

Basit Öğe Kaydı
dc.authoridOzaras, Resat/0000-0002-8130-676X
dc.authoridTahan, Veysel/0000-0001-6796-9359;
dc.authorwosidOzaras, Resat/ABB-9136-2021
dc.authorwosidTabak, Ömer Fehmi/A-1192-2018
dc.authorwosidTahan, Veysel/K-4806-2019
dc.authorwosidozaras, resat/AAO-5255-2020
dc.contributor.authorCanbakan, Mustafa
dc.contributor.authorSenturk, Hakan
dc.contributor.authorCanbakan, Billur
dc.contributor.authorToptas, Tayfur
dc.contributor.authorTabak, Omur
dc.contributor.authorOzaras, Resat
dc.contributor.authorTabak, Fehmi
dc.date.accessioned2024-06-12T11:03:06Z
dc.date.available2024-06-12T11:03:06Z
dc.date.issued2011
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Liver biopsy is an imperfect gold standard for assessing the disease severity in hemodialysis patients with chronic hepatitis C. Our purpose was to compare the accuracy of the FibroTest (FT) and ActiTest (AT) with liver biopsy and the AST-to-platelet ratio index (APRI) in determining hepatic fibrosis and necroinflammatory activity in hemodialysis patients with hepatitis C virus (HCV). Methods: The FT-AT index combining 6 biochemical markers was assessed in 33 hemodialysis patients with HCV. Liver fibrosis and necroinflammatory activity was staged and graded according to the METAVIR scoring system. Results: The accuracy of FT-AT versus biopsy was 0.46 for significant fibrosis and 0.36 for severe necroinflammatory activity. The FT index had a positive predictive value of 20% for scores greater than 0.6 and a negative predictive value of 45% for scores less than 0.2. Eleven of the 33 patients had scores <= 0.2, 6 had significant fibrosis on biopsy. Four out of 5 patients with FT scores >0.6 had mild fibrosis. APRI correlated well with the biopsy. Conclusion: The FT-AT test does not seem to be a reliable noninvasive marker for the prediction of necroinflammatory activity and fibrosis in hemodialysis patients with HCV and cannot be used as an alternative to either liver biopsy or APRI. Copyright (C) 2010 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000320751
dc.identifier.endpageC295en_US
dc.identifier.issn1660-2110
dc.identifier.issue3en_US
dc.identifier.pmid20847572en_US
dc.identifier.scopus2-s2.0-77956591216en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpageC289en_US
dc.identifier.urihttps://doi.org/10.1159/000320751
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21530
dc.identifier.volume117en_US
dc.identifier.wosWOS:000284576500018en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofNephron Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemodialysisen_US
dc.subjectChronic Hepatitis Cen_US
dc.subjectFibrotest-Actitesten_US
dc.subjectFibrosisen_US
dc.subjectNecroinflammatory Activityen_US
dc.subjectMETAVIR Scoringen_US
dc.subjectAST-To-Platelet Ratio Indexen_US
dc.subjectVirus-Infectionen_US
dc.subjectBiopsyen_US
dc.subjectAminotransferaseen_US
dc.subjectFibrotesten_US
dc.subjectAlanineen_US
dc.subjectLineen_US
dc.subjectHiven_US
dc.titleValidation of Biochemical Markers for the Prediction of Liver Fibrosis and Necroinflammatory Activity in Hemodialysis Patients with Chronic Hepatitis Cen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu